How psychedelic drugs can aid patients at the end of life

Clearly further high quality research is needed, but as this article highlights, there is encouraging evidence that psychedelics can help at the end of life. The article reports: "I believe this will be one of the next conditions, if not the next condition, to be considered for the designation of innovative treatment in future psilocybin regulation in the United States, where the field is more advanced," said Lucas Maia, PhD, a psychopharmacologist and researcher affiliated with the Advanced Center for Psychedelic Medicine (CAMP) at the Federal University of Rio Grande do Norte (UFRN) and the Interdisciplinary Cooperation for Ayahuasca Research and Outreach (ICARO) at the State University of Campinas in São Paulo, Brazil.  Currently, MDMA (for the treatment of posttraumatic stress disorder), psilocybin (for depressive disorder), and MM120 (an LSD analogue used to treat generalized anxiety disorder) are the only psychedelic substances that have received the designation of innovative treatment by the US Food and Drug Administration (FDA).  In 2022, Maia and a colleague from ICARO, Dr Ana Cláudia Mesquita Garcia, a professor at the School of Nursing at the Federal University of Alfenas in Brazil and leader of the Interdisciplinary Center for Studies in Palliative Care, published a systematic review in the Journal of Pain and Symptom Management that evaluated the use of psychedelic-assisted treatments for symptom control in patients with serious or terminal illnesses."

For more psychedelic news and research, visit the psychedelic health professional network homepage.

Previous
Previous

The psychotherapy in MDMA-assisted psychotherapy

Next
Next

The (Psilocybin) Magic Mushroom Interaction Checker